share_log

The Week Ahead In Biotech (Jan 23-29): Roche, Azurity FDA Decisions, J&J, Vertex Earnings, Samsara Vision IPO And More

The Week Ahead In Biotech (Jan 23-29): Roche, Azurity FDA Decisions, J&J, Vertex Earnings, Samsara Vision IPO And More

生物技術領域的未來一週(1月23日至29日):羅氏(Roche)、Azity FDA決策、強生(J&J)、頂點收益(Vertex收益)、Samsara Vision IPO等
Benzinga Real-time News ·  2022/01/24 00:06

Biotech stocks pulled back yet again during the week ending Jan. 21, with the sector retreating along with the broader market. The news flow tapered off following the frenetic pace of the week that encompassed the JPM Healthcare conference.

生物科技股在截至1月21日的一週內再次回落,該板塊與大盤一起回落。隨着摩根大通醫療保健會議(JPM Healthcare Conference)一週的狂熱節奏,新聞流量逐漸減少。

On the M&A front, rare disease biopharma Zogenix, Inc. (NASDAQ:ZGNX) agreed to be acquired by Belgium's UCB SA (OTC:UCBJY) for about $1.8 billion.

在併購方面,罕見病生物製藥Zgenix,Inc.納斯達克(Sequoia Capital:ZGNX)同意被比利時UCB SA(場外交易代碼:UCBJY)約18億美元。

Here are the key catalytic events biotech investors can look forward to in the unfolding week:

以下是生物技術投資者在即將展開的一週中可以期待的關鍵催化事件:

Conferences

會議

B. Riley Virtual Oncology Conference: Jan. 27-28

B.萊利虛擬腫瘤學會議:1月27日至28日

PDUFA Dates

PDUFA日期

The Food and Drug Administration is scheduled to announce by Saturday, Jan. 29, its verdict on Azurity's new drug application for zonisamide oral suspension for the treatment of partial seizures in patients with epilepsy. Azurity had purchased zonisamide oral suspension from Eton Pharmaceuticals, Inc.(NASDAQ:ETON).

美國食品和藥物管理局(Food and Drug Administration,簡稱FDA)定於1月29日(星期六)宣佈對Azity申請唑尼沙胺口服混懸劑治療癲癇患者部分癲癇發作的新藥申請的裁決。阿齊蒂從以下公司購買了唑尼沙胺口服混懸劑伊頓公學制藥公司(Eton PharmPharmticals,Inc.)(納斯達克:伊頓公學)。

Roche Holding AG (PNK: RHHBY) awaits approval for its biologic license application for faricimab as a treatment option for wet age-related macular degeneration and diabetic macular edema. The decision is expected by late January.

羅氏控股公司PNK:RHHBY)正在等待其Faricimab作為治療濕性老年性黃斑變性和糖尿病性黃斑水腫的生物許可申請的批准。這一決定預計將在1月下旬做出。

Clinical Readouts/Presentations

臨牀讀數/演示文稿

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) will present at the American Society of Clinical Oncology Plenary Series Session on Tuesday, results of the Phase 3 INTRIGUE study of Qinlock in second-line gastrointestinal stromal tumor. Zai Lab Limited (NASDAQ:ZLAB) has in-licensed the investigational asset for the Greater China region.

Deciphera製藥公司納斯達克(Sequoia Capital)(納斯達克代碼:DCPH)將於週二在美國臨牀腫瘤學會全體會議上公佈秦洛克治療二線胃腸道間質瘤的3期耐人尋味研究結果。再鼎醫藥-SB納斯達克(Sequoia Capital:ZLAB)已經為大中華區的調查資產授予了內部許可。

Cue Biopharma, Inc. (NASDAQ:CUE) will provide on Wednesday an update from its ongoing clinical trials with CUE-101, its lead and representative IL-2 based drug product candidate from the CUE-100 series. CUE-101 is currently in a Phase 1b clinical trial for the treatment of HPV+ recurrent/metastatic head and neck squamous cell carcinoma.

Cue Biophma,Inc.納斯達克公司(Temasek Holdings:CUE)將於週三提供其正在進行的CUE-101臨牀試驗的最新情況。CUE-101是CUE-100系列中基於IL-2的主要候選藥物產品,也是具有代表性的候選藥物。CUE-101目前正在進行1b期臨牀試驗,用於治療HPV陽性的復發/轉移性頭頸部鱗狀細胞癌。

Related Link: 23andMe Pivoting To Clinical Research: Could That Lead To A Turnaround For The Stock?

相關鏈接:23andMe轉向臨牀研究:這能讓股票扭虧為盈嗎?

Earnings

收益

Johnson & Johnson (NYSE:JNJ) (Tuesday, before the market open)
Abbott Laboratories (NYSE:ABT) (Wednesday, before the market open)
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) (Wednesday, after the close)
Edwards Lifesciences Corporation (NYSE:EW) (Wednesday, after the close)
ResMed Inc. (NYSE:RMD) (Thursday, after the close)

強生(紐約證券交易所代碼:JNJ)(週二,市場開盤前)
雅培(紐約證券交易所代碼:ABT)(週三,市場開盤前)
Vertex製藥公司(納斯達克:VRTX)(週三收盤後)
愛德華茲生命科學公司(紐約證券交易所股票代碼:EW)(週三收盤後)
ResMed Inc.(紐約證券交易所股票代碼:RMD)(週四收盤後)

IPOs

首次公開募股(IPO)

IPO Pricing

IPO定價

New Jersey-based Samsara Vision, Inc. (NASDAQ:SMSA) has filed a preliminary prospectus with the SEC related to its proposed initial public offering of 4.17 million shares. The medical device that focuses on treatments for late-stage conditions of the retina expects the shares to be priced between $5 and $7. It has applied for listing its common stock on the Nasdaq under the ticker symbol SMSA.

總部位於新澤西州Samsara Vision,Inc.納斯達克(Sequoia Capital:SMSA)已向美國證券交易委員會提交了一份初步招股説明書,涉及其擬發行417萬股的首次公開募股(IPO)。這家專注於治療視網膜晚期疾病的醫療設備預計發行價在5美元至7美元之間。該公司已申請將其普通股在納斯達克上市,股票代碼為SMSA。

Related Link: Attention Biotech Investors: Mark Your Calendar For January PDUFA Dates

相關鏈接:生物技術投資者請注意:將您的日曆標記為PDUFA日期為1月份

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論